Fresenius — controlled mAbxience teams with Sandoz on emicizumab biosimilar development, manufacturing
Fresenius-controlled mAbxience signed a licensing, development, manufacturing, marketing deal with Sandoz for an emicizumab biosimilar candidate. mAbxience will develop and manufacture in GMP-certified plants in Spain, Argentina; Sandoz gets exclusive global marketing rights excluding Argentina, Uruguay, Paraguay. Proj